A population of TRAIL-positive astrocytes in glioblastoma contributes to an immunosuppressive tumour microenvironment and this mechanism can be targeted with an engineered oncolytic virus to improve outcomes.
- Camilo Faust Akl
- Brian M. Andersen
- Francisco J. Quintana